• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Prestige Consumer Healthcare (PBH) Could Be 33% Undervalued As 2027 Guidance Softens

    Simply Wall St·11/13/2026 15:28:38
    Listen to the news

    Why Prestige Consumer Healthcare is in focus after new earnings and guidance

    Prestige Consumer Healthcare (PBH) drew investor attention after reporting second quarter results that paired higher sales and revenue with lower net income and earnings per share, along with a trimmed fiscal 2027 outlook for revenue and GAAP diluted EPS.

    Prestige Consumer Healthcare shares closed at US$45.32 after the results, with a 1 day share price return of 2.6% and a 7 day share price return of 2.3%. However, the 30 day and year to date share price returns, alongside the 1 year and 5 year total shareholder returns, all point to fading momentum as investors reassess the balance between revenue growth and a more cautious earnings outlook.

    Spot opportunities that rhyme with Prestige Consumer Healthcare’s setup by scanning our curated list of 32 high quality undervalued stocks, which shows revenue strength with more cautious earnings trends.

    Prestige Consumer Healthcare now trades well below both intrinsic estimates and analyst targets after that cautious 2027 guide. Is the discount signalling an opportunity, or is it simply mirroring real concern about future earnings power?

    Most Popular Narrative: 33% Undervalued

    On the analyst consensus Narrative on Simply Wall St, Prestige Consumer Healthcare screens as undervalued, with a fair value of $67.80 against the last close of $45.32, which puts a lot of weight on future cash generation and acquisition integration.

    The planned contribution of about $900 million of free cash flow over three years, supported by guidance of at least $270 million in fiscal 2027 alone, gives Prestige Consumer Healthcare room to reduce leverage and lower interest expense, which feeds directly into net income and EPS.

    See why 2 investors see Prestige Consumer Healthcare as 33% undervalued.

    Result: Fair Value of $67.80 (UNDERVALUED)

    Still, the Prestige Consumer Healthcare story could change quickly if Clear Eyes supply remains uneven or if the roughly US$2b net debt becomes harder to service.

    Find out about the key risks to this Prestige Consumer Healthcare narrative.

    Next Steps

    Sentiment around Prestige Consumer Healthcare is mixed, with real concerns and clear positives pulling in opposite directions. Investors may want to move quickly, review the data set in full, and weigh the 4 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Prestige Consumer Healthcare?

    Do not stop with Prestige Consumer Healthcare. Broaden your watchlist with fresh angles on quality, income, and resilience using focused stock ideas sourced from the Simply Wall St screener.